TTrialPathMatch Me to Trials
← Back to trials
RecruitingTransgender Women

Progesterone in Gender Affirming Hormone Therapy Study

Eligible age

18–60 yrs

Accepts

Men

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study aims to study the effects of Oral Progesterone in Transgender Women. The primary goal is to study the effect of progesterone on psychological distress and secondarily on sleep quality, breast size, quality of life and gender congruence and cardiovascular risk.

Sponsor: Emory University

You may qualify if…

  • \- Participants will be transgender women, who have been on gender-affirming hormone therapy for at least 6 months before the start of the study.

You may not qualify if…

  • Peanut allergy
  • Liver disease (liver enzyme elevations and/or evidence of acute or chronic hepatitis). In our lab, the upper limit of normal for aspartate aminotransferase (AST) is 39, and the upper limit of normal for alanine aminotransferase (ALT) is 52.
  • Stage 4/5 chronic kidney disease
  • Congestive heart failure
  • Medical disease or medication use associated with gynecomastia (i.e tumor, hyperthyroidism, chronic kidney disease, cirrhosis, ACE inhibitors, statins, haloperidol, tricyclic antidepressants, atypical antipsychotics)
  • Pre-existing cardiovascular disease
  • Prior or current history of thromboembolism, known clotting disorders, current or recent anti-thrombotic therapy for venous thromboembolism.
  • History of breast cancer

Where it's recruiting

Georgia

Atlanta

Source: ClinicalTrials.gov · NCT06807580 · last updated 2025-12-24

Progesterone in Gender Affirming Hormone Therapy Study · TrialPath